Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Heterogeneity of antibody-secreting cells infiltrating autoimmune tissues.
Giovannini D, Belbezier A, Baillet A, Bouillet L, Kawano M, Dumestre-Perard C, Clavarino G, Noble J, Pers JO, Sturm N, Huard B. Giovannini D, et al. Among authors: pers jo. Front Immunol. 2023 Feb 21;14:1111366. doi: 10.3389/fimmu.2023.1111366. eCollection 2023. Front Immunol. 2023. PMID: 36895558 Free PMC article. Review.
Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation.
Bettacchioli E, Saraux A, Tison A, Cornec D, Dueymes M, Foulquier N, Hillion S, Roguedas-Contios AM, Benyoussef AA, Alarcon-Riquelme ME, Pers JO, Devauchelle-Pensec V; PRECISESADS Clinical Consortium, and PRECISESADS Sjögren Consortium. Bettacchioli E, et al. Among authors: pers jo. Arthritis Rheumatol. 2024 May;76(5):751-762. doi: 10.1002/art.42789. Epub 2024 Feb 14. Arthritis Rheumatol. 2024. PMID: 38130019
A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases.
Simon Q, Grasseau A, Boudigou M, Le Pottier L, Bettachioli E, Cornec D, Rouvière B, Jamin C, Le Lann L; PRECISESADS Clinical Consortium; PRECISESADS Flow Cytometry Study Group; Borghi MO, Aguilar-Quesada R, Renaudineau Y, Alarcón-Riquelme ME, Pers JO, Hillion S. Simon Q, et al. Among authors: pers jo. Arthritis Rheumatol. 2021 Aug;73(8):1550-1561. doi: 10.1002/art.41697. Epub 2021 Jul 9. Arthritis Rheumatol. 2021. PMID: 33605069
High-content multimodal analysis supports the IL-7/IL-7 receptor axis as a relevant therapeutic target in primary Sjögren's syndrome.
Desvaux E, Hemon P, Soret P, Le Dantec C, Chatzis L, Cornec D, Devauchelle-Pensec V; PRECISESADS clinical consortium; Elouej S, Duguet F, Laigle L, Poirier N, Moingeon P, Bretin S, Pers JO. Desvaux E, et al. Among authors: pers jo. J Autoimmun. 2023 Dec 18:103147. doi: 10.1016/j.jaut.2023.103147. Online ahead of print. J Autoimmun. 2023. PMID: 38114349
Precision medicine in Sjögren's disease.
Gandolfo S, Bombardieri M, Pers JO, Mariette X, Ciccia F. Gandolfo S, et al. Among authors: pers jo. Lancet Rheumatol. 2024 May 6:S2665-9913(24)00039-0. doi: 10.1016/S2665-9913(24)00039-0. Online ahead of print. Lancet Rheumatol. 2024. PMID: 38723653 Review.
CD8+ tissue-resident memory T cells are expanded in primary Sjögren's disease and can be therapeutically targeted by CD103 blockade.
Mauro D, Lin X, Pontarini E, Wehr P, Guggino G, Tang Y, Deng C, Gandolfo S, Xiao F, Rui K, Huang E, Tian J, Raimondo S, Rischmueller M, Boroky J, Downie-Doyle S, Nel H, Baz-Morelli A, Hsu A, Maraskovsky E, Barr A, Hemon P, Chatzis L, Boschetti CE, Colella G, Alessandro R, Rizzo A, Pers JO, Bombardieri M, Thomas R, Lu L, Ciccia F. Mauro D, et al. Among authors: pers jo. Ann Rheum Dis. 2024 May 22:ard-2023-225069. doi: 10.1136/ard-2023-225069. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38777379
216 results